

20 August 2008

The Company Announcements Office  
Australian Stock Exchange Limited

### **Neuren Pharmaceuticals Limited Share Purchase Plan**

On 6 August 2008, Neuren Pharmaceuticals Limited (Neuren or the Company) announced that it would extend its Share Purchase Plan (SPP), offering each shareholder with a registered address in Australia or New Zealand between A\$1,000 and A\$5,000 worth of new fully paid ordinary shares in the capital of the Company.

In compliance with the New Zealand Securities Act (Neuren Pharmaceuticals Limited) Exemption Notice 2006, Neuren provides the following information:

1. The subscription price under the SPP has been set at A\$0.08 per share. This is the same price as the shares issued to institutional and sophisticated investors in the recent share placement. Documentation in relation to the SPP was sent to eligible shareholders on 15 August 2008 and the offer opened on 19 August 2008; and
2. The Board of Directors of Neuren Pharmaceuticals Limited hereby certifies that, at the time when the subscription price was fixed, Neuren Pharmaceuticals Limited had no information not publicly available that would, or would be likely to, have a material effect on the market price of the Company's shares if the information were publicly available.

Signed by each of the directors of  
Neuren Pharmaceuticals Limited,  
or by his agent:



Dr Robin Congreve  
Chairman




Dr Doug Wilson  
Director



Mr Trevor Scott  
Director



Mr Tom Amos  
Director



Dr Graeme Howie  
Director